10 December 2018 | News
A blood test for Alzheimer's disease could be administered easily and repeatedly, with patients going to their primary care office rather than having to go into a hospital
Scientists have developed a blood test that can accurately diagnose or even predict Alzheimer's disease before symptoms appear.
Currently the only way to definitively diagnose Alzheimer's disease in life is through brain scans and tests of cerebrospinal fluid that must be collected via lumbar puncture.
Researchers at Brigham and Women's Hospital are working to develop a blood test that could replace these procedures to accurately diagnose or even predict Alzheimer's disease before symptoms appear.
The tau protein has long been implicated in Alzheimer's, however, tau occurs as a family of related molecules which have subtly different properties.
The team took advantage of the complexity of tau and built assays to measure different forms of tau and identified a subset of tau proteins which are specifically elevated in Alzheimer's disease.
“A blood test for Alzheimer's disease could be administered easily and repeatedly, with patients going to their primary care office rather than having to go into a hospital," said corresponding author Dominic Walsh, PhD, of the Ann Romney Center for Neurologic Diseases at the Brigham. "Ultimately, a blood-based test could replace cerebrospinal fluid testing and/or brain imaging. Our new test has the potential to do just that. Our test will need further validation in many more people, but if it performs as in the initial two cohorts, it would be a transformative breakthrough."
Walsh and colleagues developed tests capable of detecting different populations of tau fragments in cerebrospinal fluid and blood. They applied these tests to participants who had donated both plasma and cerebrospinal fluid. They validated results in a second group of patients.
The team analysed five different tests for tau fragments, finding that one, known as the NT1 assay, showed sufficient ability to predict AD cases and exclude controls to pursue its use as a potential screening tool for Alzheimer's disease. This was confirmed in both sets of patients.
While performing the experiment twice - in two sets of patients with two different demographic backgrounds - provided important confirmation, the authors note that both groups of participants were small (65 participants and 86 participants, respectively).
Larger groups of participants will need to be studied. Researchers are also interested in studying patients over time to determine how tau levels in blood may change as the disease progresses and what those numbers may look like before the onset of symptoms.
"We've made our data and the tools needed to perform our test widely available because we want other research groups to put this to test," said Walsh. "It's important for others to validate our findings so that we can be certain this test will work across different populations."